Sanofi and Glooko partner on ‘connected insulin’ tech

pharmafile | February 24, 2023 | News story | Medical Communications  

Big pharma company Sanofi aims to develop insulin-based therapies that can be connected with glucose monitoring devices, making it easier for patients with the management of their blood glucose levels.

In a next step towards achieving this, Sanofi have formed another partnership to further its insulin-based therapies. This time the company has partnered with Glooko, a digital health company that has developed software allowing glucose and insulin dosing data to be managed digitally and shared between patients and healthcare providers.

Due to the competitive nature of the insulin market, companies such as Sanofi, Novo Nordisk and Eli Lilly have begun adding additional technologies to their products in order to increase their value to customers.

This partnership means Glooko’s software will be integrated with Sanofi’s SoloSmart device, converting the company’s SoloStar and DoubleStar insulin injector pens into connected devices which allow the patients to record their insulin doses, dates and times of injection.

The data can be recorded in the Glooko app, which can then be reviewed by the patient or shared with their healthcare providers.

Although SoloSmart hasn’t been approved in the US yet, it has been approved elsewhere and is expected to marketed in various countries this year.

Russ Johannesson, chief executive officer of Glooko, commented: “We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies. Glooko is the first diabetes data management platform to launch with SoloSmart, something our team is particularly proud of. This will allow us to further expand our global reach aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”

Jared Josleyn, global head of Digital Healthcare at Sanofi, added: “At Sanofi, we believe that we will deliver value to people living with diabetes by building an ecosystem with local and global partners. With Biocorp, SoloSmart’s manufacturer, Glooko, a leading digital health solution that supports patients and healthcare partners, and local partners, we aim to improve daily management for individuals living with diabetes. For 100 years, Sanofi has been at the forefront of managing diabetes. We continue to build on this heritage with a vision and commitment to help transform diabetes care for 537 million people living with diabetes around the world.”


Betsy Goodfellow

Related Content

No items found

Latest content